This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly Begins Phase III Study on Olumiant for Coronavirus
by Zacks Equity Research
Lilly's (LLY) Olumiant is being studied for COVID-19 on the assumption that JAK1 and JAK2 inhibition may reduce cytokine storm, a complication associated with COVID-19.
Top Analyst Reports for Procter & Gamble, Eli Lilly & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Eli Lilly (LLY) and Thermo Fisher Scientific (TMO).
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $141.52, marking a -1.41% move from the previous day.
Glaxo (GSK) HIV Drug Tivicay Gets FDA Approval for Toddlers
by Zacks Equity Research
FDA approves Glaxo's (GSK) oral suspension formulation of its three-drug regimen for HIV, Tivicay, as a treatment for patients aged at least four weeks and weighing at least 3kg.
Merck's Gardasil Gets FDA Approval for Head and Neck Cancers
by Zacks Equity Research
FDA grants accelerated approval for label expansion application of Merck's (MRK) human papillomavirus vaccine, Gardasil, to include oropharyngeal and other head and neck cancers.
This is Why Eli Lilly (LLY) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals
by Kinjel Shah
J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.
AbbVie Inks Deal With Genmab, Announces ADC Candidate Data
by Zacks Equity Research
AbbVie (ABBV) signs deal with Genmab to jointly develop three early-stage bispecific antibody product candidates. Its novel ADC candidate, ABBV-3373 demonstrates clinical activity in study.
Pfizer's Eczema Candidate Meets All Goals in Study on Teens
by Zacks Equity Research
Pfizer's (PFE) investigational eczema treatment, abrocitinib, succeeds in a late-stage study under the JADE program in patients aged 12 years and above.
Company News for Jun 11, 2020
by Zacks Equity Research
Companies In The News Are: LLY, VRNT, SBUX, TCO, SPG.
ESG Investing Trend to Stay Strong Post Pandemic: 5 Top Picks
by Zacks Equity Research
Investing in ESG stocks bear lesser financial risks due to their focus on environment, employees and supply chain. They proved resilient during the coronavirus pandemic and will continue to surge.
Lilly Begins Cardiovascular Outcomes Study on Tirzepatide
by Zacks Equity Research
Lilly (LLY) announces that the first patient dose has been delivered in a cardiovascular outcome study on its novel diabetes candidate, tirzepatide.
Lilly's 2nd Potential Coronavirus Antibody Candidate in Phase I
by Zacks Equity Research
Lilly (LLY) is set to study JS016 as a monotherapy and in combination with antibody treatments including LY-CoV555, its first potential COVID-19 antibody candidate that recently entered phase I.
Hexo Corp. (HEXO) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Hexo's (HEXO) fiscal third-quarter results are likely to reflect operational efficiency and strong product portfolio.
Eli Lilly (LLY) Flat As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $149.21, marking no change from the previous day.
Merck's Antibiotic Recarbrio Gets FDA Nod for New Indication
by Zacks Equity Research
The FDA approves Merck's (MRK) sNDA seeking approval for its antibacterial injection Recarbrio regarding a new indication. The application was filed in February 2020.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
AstraZeneca's Calquence Shows Promise as Coronavirus Treatment
by Zacks Equity Research
Peer-reviewed data on AstraZeneca's (AZN) Calquence shows that it improves laboratory markers of inflammation and decreases oxygen requirements in most patients hospitalized due to COVID-19.
Cooper Companies (COO) Misses on Q2 Earnings and Revenues
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter earnings reflect dismal segmental performance and decline in revenues.
Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential COVID-19 antibody therapy. FDA grants label expansion approvals to several drugs.
Novartis (NVS) Announces Positive Data From Cosentyx Study
by Zacks Equity Research
Novartis (NVS) reports encouraging data from the phase III PREVENT study evaluating Cosentyx in patients with non-radiographic axial spondyloarthritis.
Roche's COVID-19 Test Gets FDA's Emergency Use Authorization
by Zacks Equity Research
Roche's (RHHBY) Elecsys IL-6 test gets FDA's EUA for identifying patients at high risk of severe inflammatory response.
Change Healthcare (CHNG) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal fourth-quarter results benefit from solid performance across the Network Solutions segment and higher revenues.
How Are Biotech ETFs Reacting to Coronavirus Treatment News?
by Sweta Jaiswal, FRM
Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.
Bristol Myers' Zeposia Meet Goals in Ulcerative Colitis Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage study of Zeposia in patients with moderate-to-severe ulcerative colitis meets both its main goals.